https://www.biosciencedesk.com/news/halozyme-blocks-merck-subcutaneous-keytruda-launch-europe-patent-injunction BioScienceDesk en 2026-10-09T10:16:12.006Z Halozyme Wins Dutch Injunction Against Merck’s Subcutaneous Keytruda in Eight European Countries Keytruda SC, Keytruda Qlex, Merck, Halozyme Therapeutics, Alteogen, Berahyaluronidase Alfa https://www.biosciencedesk.com/news/fda-approves-pfizer-tukysa-her2climb-05-1l-maintenance-her2-breast-cancer BioScienceDesk en 2026-10-08T10:30:00.000Z FDA Approves Tukysa as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer Pfizer, Tukysa, Tucatinib, HER2-Positive, Metastatic Breast Cancer, FDA Approval https://www.biosciencedesk.com/news/abbvie-telisotuzumab-adizutecan-dual-fda-breakthrough-crc-nsclc-cmet-adc BioScienceDesk en 2026-10-07T10:30:00.000Z FDA Grants Two Breakthrough Therapy Designations to AbbVie's c-Met ADC Temab-A in Colorectal and Lung Cancer AbbVie, Telisotuzumab Adizutecan, Temab-A, ABBV-400, c-Met ADC, Colorectal Cancer